Literature DB >> 8184545

Adsorption and penetration of hepatitis B virus in a nonpermissive cell line.

M Qiao1, T B Macnaughton, E J Gowans.   

Abstract

A cell monolayer radioimmunoassay was established to detect hepatitis B virus (HBV)-binding activity. HBV was shown to bind to HepG2 and HuH7 cells, but not to LTK- and HeLa cells. The binding activity was inhibited by peptide 21-47 from the large hepatitis B surface antigen (L-HBsAg) region, but not by other peptides from the L- and middle-HBsAg. A monoclonal antibody to L-HBsAg (MA18/7) and a polyclonal antibody to HBsAg (anti-HBs) also inhibited the binding. However, only the Fab fragment of MA18/7 showed blocking activity, suggesting that these two antibodies may neutralize virus by different mechanisms. Excess HBV was able to saturate the binding activity of HepG2 cells. The virus was also shown to be internalized; virus DNA was detected in the cytoplasmic fraction 1-2 hr postadsorption and was associated with the nuclear fraction 2 hr later. Furthermore, immunoprecipitation experiments showed that the virus DNA remained encapsidated 48 hr after internalization. Nuclear fractionation experiments showed that the encapsidated HBV DNA remained associated with the nuclear membrane. Trypsinization of intact nuclei resulted in disassociation of the nucleocapsid from the nuclear membranes, suggesting that the nuclear membrane presents a barrier to intact HBV virions or nucleocapsids. This may explain why HepG2 cells are refractile to infection although permissive for HBV replication after transfection of viral DNA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8184545     DOI: 10.1006/viro.1994.1301

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

Review 1.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  In vitro model for the nuclear transport of the hepadnavirus genome.

Authors:  M Kann; A Bischof; W H Gerlich
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  Hydrophobicity of reactive site loop of SCCA1 affects its binding to hepatitis B virus.

Authors:  Min Chen; Tong Cheng; Chen-Yu Xu; Ting Wu; Shan-Hai Ou; Tao Zhang; Jun Zhang; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

4.  HBV infection of cell culture: evidence for multivalent and cooperative attachment.

Authors:  N Paran; B Geiger; Y Shaul
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

5.  Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line.

Authors:  X Lu; T M Block; W H Gerlich
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 6.  HBV culture and infectious systems.

Authors:  C Nelson Hayes; Kazuaki Chayama
Journal:  Hepatol Int       Date:  2016-03-02       Impact factor: 6.047

7.  Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.

Authors:  Hong Chen; Xia Chuai; Yao Deng; Bo Wen; Wen Wang; Shaoqing Xiong; Li Ruan; Wenjie Tan
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex.

Authors:  M Kann; B Sodeik; A Vlachou; W H Gerlich; A Helenius
Journal:  J Cell Biol       Date:  1999-04-05       Impact factor: 10.539

9.  Study of the early steps of the Hepatitis B Virus life cycle.

Authors:  Xuanyong Lu; Timothy Block
Journal:  Int J Med Sci       Date:  2004-03-10       Impact factor: 3.738

10.  Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages.

Authors:  Masaharu Murata; Sayoko Narahara; Kaori Umezaki; Riki Toita; Shigekazu Tabata; Jing Shu Piao; Kana Abe; Jeong-Hun Kang; Kenoki Ohuchida; Lin Cui; Makoto Hashizume
Journal:  Int J Nanomedicine       Date:  2012-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.